Dr. Johnson is a clinical neuropsychologist with research interests in early identification of Alzheimer's disease and related disorders. He leads the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a longitudinal cohort study of 1500+ people at varying levels of risk for sporadic Alzheimer's disease. He is the associate director and Biomarker Core leader in the Wisconsin ADRC, as well as the associate director of the Wisconsin Alzheimer's Institute. 

Dr. Kukull's research is focused on the neurodegenerative, vascular and other conditions causing dementia and cognitive impairment. These conditions include Alzheimer's disease, Parkinson's/Lewy body disease, frontotemporal lobar degeneration, and cerebrovascular disease. Since 1999, he has served as Director and PI of the National Alzheimer's Coordinating Center [U24 AG072122], an effort to collect and make available to researchers standardized, detailed clinical data from the approximately 37 NIA-funded Alzheimer Disease Centers across the United States. Dr. Kukull works closely with the leadership of the ADRCs and the National Institute on Aging to ensure that scientifically relevant and valid data are obtained and available from NACC’s database to any researcher anywhere.

In addition to NACC work, he is an investigator with a number of other NIH grants. He is an elected Fellow of: American College of Epidemiology, American Academy of Neurology and American Association for Advancement of Science.

Dr. David Wolk is Professor of Neurology, Chief of the Division of Cognitive Neurology, Director of the National Institute of Aging funded Penn Alzheimer’s Disease Research Center, and Co-Director of the Penn Institute on Aging.

Dr. Wolk’s primary clinical interest has been in the diagnosis and care of individuals with a variety of neurodegenerative conditions. His research has focused on the cognitive neuroscience of memory decline associated with aging and Alzheimer’s Disease using techniques including behavioral testing, structural and functional MRI, and FDG and molecular PET imaging. Much of this work is also directed at examining biomarkers, including behavioral and neuroimaging, that differentiate healthy aging from the earliest transition to AD and their potential role in understanding disease mechanisms and incorporation into treatment trials. Dr. Wolk has had sustained NIH support since 2003 and has been the principal or co-investigator on numerous local, national and international studies, including therapeutic trials.

Dr. Wolk completed his medical training at Johns Hopkins University, a Neurology residency at the University of Pennsylvania, and clinical Fellowship training in Cognitive and Behavioral Neurology at Brigham and Women’s Hospital/Harvard Medical School; where he also completed a post-doctoral research fellowship studying memory in Alzheimer’s Disease. Amongst a number of honors, he is the recipient of the American Academy of Neurology’s Norman Geschwind Prize in Behavioral Neurology.

Dr. Gil Rabinovici holds the Edward Fein and Pearl Landrith Distinguished Professorship in Memory & Aging in the UCSF Department of Neurology. He received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC), where he cares for patients with cognitive disorders.

Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and study the biology of neurodegenerative diseases, with the goal of accelerating drug development. He is the director of the NIH-funded UCSF Alzheimer’s Disease Research Center, study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies (~25,000 total participants), as well as co-PI on the emerging Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), co-PI and PET Core lead of the Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS) and PI on several additional national and local clinical, imaging and translational studies focused on Alzheimer’s disease and related disorders. His work is supported by the NIH, Alzheimer’s Association, American College of Radiology, Rainwater Charitable Foundation and industry partners. He has authored over 290 peer-reviewed publications, and the impact of his work is ranked in the top 1% in the field of Neuroscience.

Dr. Rabinovici’s contributions have been recognized with numerous awards, including the 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging,  2015 Christopher Clark Award in Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 de Leon Prize from the Alzheimer’s Association.

Dr. Okonkwo is a Professor in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health. His research focuses on clarifying how alterations in the brain and other biomolecules place some cognitively-normal individuals on a pernicious trajectory that culminates in symptomatic Alzheimer’s disease. In this context, Dr. Okonkwo is also interested in discovering new knowledge concerning the modulation of the link between brain changes and cognitive decline by both modifiable and non-modifiable factors. Overlaid on this research agenda are investigations of health inequities, and how such inequities exacerbate or ameliorate the impact of biomarkers on clinical phenotypes. Dr Okonkwo is passionate about mentoring emerging leaders in the field, and co-directs the NIH-funded Health Equity Scholars Program

Dr. Nathaniel Chin is an associate professor in the Department of Medicine and Division of Geriatrics and Gerontology. Dr. Chin sees patients in the UW Health Memory Clinic where he also serves as the Associate Program Director. His clinical focus is on the early identification of cognitive impairment and the development of a holistic approach to care post-diagnosis. He is the medical director of the WI Alzheimer’s Disease Research Study and the Wisconsin Registry for Alzheimer’s Prevention Study. His research focuses on understanding the perceptions and implications of biomarker disclosure as well as the effect of addressing modifiable risk factors. He has created over 170 podcasts on AD research and caregiving topics under his podcast called Dementia Matters.

Dr. Lindsay Clark is a faculty member in the Division of Geriatrics and Gerontology in the Department of Medicine. As a neuropsychologist specializing in geriatrics, Dr. Clark provides diagnostic assessments and treatment planning as part of the UW Sauk Prairie Outreach clinic and VA Geriatric Research Education and Clinical Center (GRECC) Connect Teledementia and Cognitive Care Clinics.

She leads research projects to address barriers to early detection of cognitive impairment, including developing best practices for disclosure of AD biomarker results as well as investigating the feasibility, reliability, and validity of digital cognitive tools and direct-to-home televideo memory evaluations. She collaborates on large multi-site studies, including leading the Neuropsychology service within the Wisconsin Alzheimer’s Disease Research Center and serving as site PI for a national study evaluating video-based cognitive assessment.

Dr. Sarah Biber is the Executive Director for the National Alzheimer’s Coordinating Center (NACC), based at the University of Washington. NACC serves as the data, communication, and collaboration hub, and centralized data repository for NIA’s National Alzheimer’s Disease Research Centers (ADRC) Program, comprised of 33 centers across the United States. NACC is home to one of the largest (48,600+ participants), oldest, and most powerful AD/ADRD datasets. Dr. Biber co-leads NACC’s scientific and strategic direction and $58 million project and grant portfolio with NACC PI and Director, Dr. Walter Kukull. Within this role, she represents NACC with national partners, spearheads national initiatives, leads development of major grant applications, leads academic and industry partnerships, and oversees NACC’s tech, operations, research, communications, and grants and finance teams. Under her leadership, NACC is modernizing data infrastructure and expanding interoperability across the national Alzheimer’s Disease and Related Dementia (ADRD) ecosystem to advance research and discovery. She has a PhD in molecular and cellular biology and extensive experience leading strategy for complex centers and programs focused on advancing research and innovation.

Prior to joining NACC in November 2021, Dr. Biber led the Surgical Innovation Program at Oregon Health and Science University (OHSU) where she shaped and significantly expanded the department of surgery’s innovation capacity and footprint, co-developed surgical innovations, led academic and industry partnerships, and founded the OHSU Invent-a-thon. She previously served as the Assistant Director for NIH’s National Center for Data to Health (CD2H), where she was instrumental in launching the center and led operations to advance informatics innovation, data sharing, software development, and collaboration across the 50+ Clinical Translational Science Awards Program Centers. Prior to CD2H, she was Entrepreneurial Program Director at the Oregon Bioscience Incubator where she helped grow the incubator three-fold and spearheaded statewide partnerships to advance entrepreneurship and startups, served on state-wide committees, and co-founded Accelerate Biotech and Digital Health PDX.

Dr. Keene received his education at the University of Nevada, Las Vegas (B.S. in Cell and Molecular Biology) and the University of Minnesota (M.D. and Ph.D. in Neuroscience). His post-graduate medical training in Anatomic Pathology and Neuropathology was at the University of Washington where he earned a faculty position in Neuropathology. Currently, Dr. Keene is the Nancy and Buster Alvord Endowed Chair in Neuropathology, Professor of Pathology, Adjunct Associate Professor of Ophthalmology and Neurological Surgery, Director of the Neuropathology Division, and Leader of the Neuropathology and Targeted Molecular Testing Core at the University of Washington.

Dr. Keene is Board Certified in Anatomic Pathology and Neuropathology and regularly attends on each of the clinical neuropathology subspecialties (neurosurgical, neuromuscular, ophthalmic, and autopsy) for UW Medicine. He enjoys significant teaching and training opportunities through diverse teaching commitments, the UW Graduate School course “PATH513: Molecular Mechanisms of Neurodegeneration”, and as Director of the Neuropathology Fellowship.

Dr. Keene strives to promote scientific advancement through diagnostic and research neuropathology. Dr. Keene supervises a team of scientists, fellows, research coordinators, and histotechnologists who respectfully and expeditiously perform research autopsies in a manner that maximally and optimally preserves tissues for diverse applications for investigators around the country whilst providing accurate and timely neuropathological diagnoses according to the latest guidelines.

Dr. Keene energetically promotes tissue and data sharing, and facilitation of local and national research through collaborative and cooperative mechanisms. He strives to adapt existing and develop novel technologies to maximize the scientific utility of archived and prospectively acquired human brain tissue. The goal of the Keene Laboratory is to facilitate development of diagnostic, therapeutic, and preventative approaches for neurodegenerative disease by combining traditional and precision neuropathological strategies in human tissues with experimental approaches in model systems.

Dr. Rosen is a behavioral neurologist and holds the Dorothy Kirsten French Foundation Endowed Professorship for Parkinsonian and Other Neurodegenerative Disorders. He received his medical degree from Boston University School of Medicine, trained in internal medicine at the Albert Einstein College of Medicine in New York, and subsequently completed a neurology residency at UCSF. After residency, Dr. Rosen pursued fellowship training in brain imaging at the Washington University School of Medicine, and then returned to UCSF to join the team at the Memory and Aging Center (MAC) in 1999.

Dr. Rosen’s primary research interest is in the effects that atypical neurodegenerative diseases, in particular frontotemporal dementia, have on the brain, especially the emotional systems. His current projects use psychophysiology and imaging to examine how these diseases affect self-awareness and to determine how imaging and other biological markers can be used to track and to anticipate how these diseases affect the brain over time. He is also the director of education and outreach for the education core at UCSF’s Alzheimer’s Disease Research Center.

As part of the Memory and Aging Center, the Global Brain Health Institute and the UCSF Department of Neurology, he participates in the training of medical students, residents and fellows, and he participates in the evaluation of new patients in the MAC clinic as well as the continued management of care for individuals in the continuity clinic.

Paul Thompson is a Professor in the Keck School of Medicine of USC, and associate director for the Stevens Neuroimaging & Informatics Institute at USC. His team’s research projects focus on neuroscience, mathematics, computer science, software engineering and clinical aspects of neuroimaging and brain mapping.

The ENIGMA Consortium, led by Thompson since 2009, performs some of the largest-ever studies of the human brain, analyzing brain scans of more than 100,000 people worldwide. This collaborative group studies over 30 brain diseases in 45 countries, focusing on the interaction between brain health and genetics. ENIGMA has published some of the largest-ever neuroimaging studies of schizophrenia, major depression, bipolar disorder, epilepsy, autism spectrum disorder, and obsessive–compulsive disorder, and has discovered over 500 genomic loci that affect brain aging and development.

In 2020, Thompson launched AI4AD, a NIA-funded consortium, to develop AI tools to analyze and integrate genetic, imaging, and cognitive data relating to Alzheimer’s disease.

In 2023, Thompson launched the India ENIGMA Initiative, a study of factors that affect brain aging and mental health in India. Dr Thompson received the 2023 Pioneer in Medicine Award from the Society for Brain Mapping and Therapeutics, and commonly lectures on clinical neuroimaging and AI methods.

John A. Detre, M.D. is Professor of Neurology and Radiology at the Perelman School of Medicine where he is founding Director of the Center for Functional Neuroimaging in the Department of Radiology and serves as Vice Chair for Research in Neurology. He received his bachelors and medical degrees from Yale, completed fellowships in biophysics at both Carnegie Mellon University and the University of Pennsylvania, and completed neurology residency at Penn, where he has been on the faculty since 1993. Dr. Detre is also among the core faculty of the Center for Cognitive Neuroscience, currently serving as interim co-director of this Center.

Dr. Detre has been continuously funded by NIH since 1993 and is the author of over 250 original manuscripts. Drawing upon his interdisciplinary training, collaborations, and leadership skills, Dr. Detre has provided core support for neuroimaging research on the Penn Campus through an NIH funded P30 Center Core in Neuroscience Neuroimaging that is now in its eleventh year and through the Center for Magnetic Resonance and Optical Imaging, where he leads a core on imaging brain structure and function. Dr. Detre has also been extremely active in mentoring of trainees from both biophysical and biomedical backgrounds. He has been the recipient of a Mid-career Award in Patient Oriented Research and Mentoring and an NIH training grant in neuroscience neuroimaging. He currently serves as Principal Investigator of an NIH training grant targeting the career development of academically oriented neurology residents and fellows, and he serves as a mentor for several trainees and junior faculty at Penn and neighboring institutions pursuing careers in biomedical neuroimaging.